DVHGF (Devonian Health Group) Total Current Liabilities: $1.16 Mil (As of Apr. 2026)


DVHGF Devonian Health Group Inc DVHGF
49 GF Score
Price $7.00
GF Value $2.06
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Devonian Health Group Total Current Liabilities?

Devonian Health Group DVHGF 49 Total Current Liabilities is $1.16 Mil as of Apr. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $2.06 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Devonian Health Group's total current liabilities for the quarter that ended in Apr. 2026 was $1.16

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Devonian Health Group Total Current Liabilities Related Terms

Devonian Health Group Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Devonian Health Group's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devonian Health Group Total Current Liabilities Chart

Devonian Health Group Annual Data
Trend Jun16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 1.33 3.68 12.21 4.83

Devonian Health Group Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.04 4.83 4.22 1.15 1.16
DVHGF
49GF Score
Devonian Health Group Inc DVHGF
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Devonian Health Group Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Devonian Health Group's Total Current Liabilities for the fiscal year that ended in Jul. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.797+0.035
+Other Current Liabilities+Current Deferred Liabilities
=-0.00099999999999945+0
=4.83

Devonian Health Group's Total Current Liabilities for the quarter that ended in Apr. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.099+0.059
+Other Current Liabilities+Current Deferred Liabilities
=-0.00099999999999989+0
=1.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $1.16 Mil mean?
Devonian Health Group (DVHGF) has a Total Current Liabilities of $1.16 Mil as of Apr. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Devonian Health Group and its competitors.
Is Devonian Health Group's Total Current Liabilities too high?
Devonian Health Group's current Total Current Liabilities is $1.16 Mil. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Total Current Liabilities compare to VRTX and REGN?
Devonian Health Group's Total Current Liabilities of $1.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Devonian Health Group and its competitors. Devonian Health Group's current Total Current Liabilities is $1.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.06, compared to a current price of $7.00 — trading 239.8% above its estimated fair value. The current Total Current Liabilities is $1.16 Mil. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Total Current Liabilities is $1.16 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Devonian Health Group (DVHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued. The current stock price of $7.00 is trading 239.8% above its estimated GF Value™ of $2.06. GuruFocus considers Devonian Health Group to be Significantly Overvalued.

Key valuation signals for DVHGF:

  • Total Current Liabilities: $1.16 Mil
  • GF Value™: $2.06 vs. price of $7.00 (239.8% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Devonian Health Group Business Description

Other Exchanges GSD:Canada
Address 360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score

Get the complete analysis for DVHGF

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$2.06
GF Value